![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Seqirus’s Pandemic Influenza Vaccine Gets FDA Approval
Seqirus’s Pandemic Influenza Vaccine Gets FDA Approval
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
The FDA approved Seqirus’ Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to protect individuals six months or older against influenza A (H5N1).
The novel vaccine combines MF59 adjuvant and cell-based antigen manufacturing. The product is designed to be stockpiled for use by first responders in case of pandemic.
The approval makes Audenz the first adjuvanted, cell-based influenza vaccine designed to protect against influenza A in the event of a pandemic.
Upcoming Events
-
21Oct